Impaired Pulmonary Arterial Vasoconstriction and Nitric Oxide–Mediated Relaxation Underlie Severe Pulmonary Hypertension in the Sugen-Hypoxia Rat Model

Pulmonary vasoreactivity could determine the responsiveness to vasodilators and, in turn, the prognosis of pulmonary hypertension (PH). We hypothesized that pulmonary vasoreactivity is impaired, and we examined the underlying mechanisms in the Sugen-hypoxia rat model of severe PH. Male Sprague-Dawley rats were injected with Sugen (20 mg/kg s.c.) and exposed to hypoxia (9% O2) for 3 weeks, followed by 4 weeks in normoxia (Su/Hx), or treated with Sugen alone (Su) or hypoxia alone (Hx) or neither (Nx). After hemodynamic measurements, the heart was assessed for right ventricular hypertrophy (Fulton’s index); the pulmonary artery, aorta, and mesenteric arteries were isolated for vascular function studies; and contractile markers were measured in pulmonary arteries using quantitative polymerase chain reaction (PCR). Other rats were used for morphometric analysis of pulmonary vascular remodeling. Right ventricular systolic pressure and Fulton’s index were higher in Su/Hx versus Su, Hx, and Nx rats. Pulmonary vascular remodeling was more prominent in Su/Hx versus Nx rats. In pulmonary artery rings, contraction to high KCl (96 mM) was less in Su/Hx versus Nx and Su, and phenylephrine-induced contraction was reduced in Su/Hx versus Nx, Hx, and Su. Acetylcholine (ACh)-induced relaxation was less in Su/Hx versus Nx and Hx, suggesting reduced endothelium-dependent vasodilation. ACh relaxation was inhibited by nitric oxide synthase (NOS) and guanylate cyclase blockade in all groups, suggesting a role of the NO-cGMP pathway. Nitrate/nitrite production in response to ACh was less in Su/Hx versus Nx, supporting reduced endothelial NO production. Sodium nitroprusside (10−8 M) caused less relaxation in Su/Hx versus Nx, Hx, and Su, suggesting a decreased responsiveness of vascular smooth muscle (VSM) to vasodilators. Neither contraction nor relaxation differed in the aorta or mesenteric arteries of all groups. PCR analysis showed decreased expression of contractile markers in pulmonary artery of Su/Hx versus Nx. The reduced responsiveness to vasoconstrictors and NO-mediated vasodilation in the pulmonary, but not systemic, vessels may be an underlying mechanism of severe PH in Su/Hx rats and appears to involve attenuation of the NO relaxation pathway and a switch of pulmonary VSM cells to a synthetic less reactive phenotype.

[1]  M. Humbert,et al.  Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[2]  R. Khalil,et al.  Protein Kinase C as Regulator of Vascular Smooth Muscle Function and Potential Target in Vascular Disorders. , 2017, Advances in pharmacology.

[3]  N. Voelkel,et al.  Endothelial hyperpermeability in severe pulmonary arterial hypertension: role of store-operated calcium entry. , 2016, American journal of physiology. Lung cellular and molecular physiology.

[4]  D. Stewart,et al.  Marked Strain-Specific Differences in the SU5416 Rat Model of Severe Pulmonary Arterial Hypertension. , 2016, American journal of respiratory cell and molecular biology.

[5]  M. Iglarz,et al.  Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension , 2015, Journal of cardiovascular pharmacology.

[6]  Wei Li,et al.  Estrogen Receptor Subtypes Mediate Distinct Microvascular Dilation and Reduction in [Ca2+]i in Mesenteric Microvessels of Female Rat , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[7]  K. Stenmark,et al.  The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes. , 2015, American journal of physiology. Lung cellular and molecular physiology.

[8]  Wei Li,et al.  Downregulation of Microvascular Endothelial Type B Endothelin Receptor Is a Central Vascular Mechanism in Hypertensive Pregnancy , 2014, Hypertension.

[9]  A. Alzoubi,et al.  TRPC4 inactivation confers a survival benefit in severe pulmonary arterial hypertension. , 2013, The American journal of pathology.

[10]  N. Westerhof,et al.  SuHx rat model: partly reversible pulmonary hypertension and progressive intima obstruction , 2013, European Respiratory Journal.

[11]  G. Visner,et al.  Endothelial indoleamine 2,3-dioxygenase protects against development of pulmonary hypertension. , 2013, American journal of respiratory and critical care medicine.

[12]  M. Humbert,et al.  Pulmonary arterial hypertension , 2013, Orphanet Journal of Rare Diseases.

[13]  C. O’Donnell Severe pulmonary arterial hypertension , 2013, Radiopaedia.org.

[14]  R. Khalil,et al.  Molecular Mechanisms Regulating the Vascular Prostacyclin Pathways and Their Adaptation during Pregnancy and in the Newborn , 2012, Pharmacological Reviews.

[15]  S. Kourembanas,et al.  Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[16]  K. Hunter,et al.  Pulmonary vascular stiffness: measurement, modeling, and implications in normal and hypertensive pulmonary circulations. , 2011, Comprehensive Physiology.

[17]  L. Shimoda,et al.  Enhancement of myofilament calcium sensitivity by acute hypoxia in rat distal pulmonary arteries. , 2011, American journal of physiology. Lung cellular and molecular physiology.

[18]  N. Voelkel,et al.  Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial Hypertension , 2010, Circulation.

[19]  A. Tonelli,et al.  Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. , 2010, Respiratory medicine.

[20]  Sally H Vitali,et al.  Impaired Vasoconstriction and Nitric Oxide-Mediated Relaxation in Pulmonary Arteries of Hypoxia- and Monocrotaline-Induced Pulmonary Hypertensive Rats , 2010, Journal of Pharmacology and Experimental Therapeutics.

[21]  Kurt R Stenmark,et al.  Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[22]  A. Pries,et al.  Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease* , 2009, Critical care medicine.

[23]  Mario J. Garcia,et al.  Evaluation of pulmonary artery stiffness in pulmonary hypertension with cardiac magnetic resonance. , 2009, JACC. Cardiovascular imaging.

[24]  J. Stehlik,et al.  Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure. , 2009, Journal of cardiac failure.

[25]  C. Burger Pulmonary Hypertension in COPD: A Review and Consideration of the Role of Arterial Vasodilators , 2009, COPD.

[26]  R. Khalil,et al.  Differential [Ca2+]i signaling of vasoconstriction in mesenteric microvessels of normal and reduced uterine perfusion pregnant rats. , 2008, American journal of physiology. Regulatory, integrative and comparative physiology.

[27]  M. Skokan,et al.  Evidence for cell fusion is absent in vascular lesions associated with pulmonary arterial hypertension. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[28]  M. Oka,et al.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension , 2008, British journal of pharmacology.

[29]  Robin Shandas,et al.  Changes in the structure-function relationship of elastin and its impact on the proximal pulmonary arterial mechanics of hypertensive calves. , 2008, American journal of physiology. Heart and circulatory physiology.

[30]  C. Knoderer,et al.  Use of Sildenafil to Facilitate Weaning From Inhaled Nitric Oxide in Children With Pulmonary Hypertension Following Surgery for Congenital Heart Disease , 2008, Journal of intensive care medicine.

[31]  M. Oka,et al.  Endothelin-1 and Serotonin are Involved in Activation of RhoA/Rho Kinase Signaling in the Chronically Hypoxic Hypertensive Rat Pulmonary Circulation , 2007, Journal of cardiovascular pharmacology.

[32]  S. Archer,et al.  The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted , 2007, Proceedings of the National Academy of Sciences.

[33]  Kurt R Stenmark,et al.  Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[34]  N. Voelkel,et al.  Rho Kinase-Mediated Vasoconstriction Is Important in Severe Occlusive Pulmonary Arterial Hypertension in Rats , 2007, Circulation research.

[35]  E. Nozik-Grayck,et al.  Role of reactive oxygen species in chronic hypoxia-induced pulmonary hypertension and vascular remodeling. , 2007, Advances in experimental medicine and biology.

[36]  F. Faraci,et al.  Endothelium-Derived Hyperpolarizing Factor: Where Are We Now? , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[37]  B. Fanburg,et al.  Hypoxia and hypoxia-inducible factor-1alpha promote growth factor-induced proliferation of human vascular smooth muscle cells. , 2006, American journal of physiology. Heart and circulatory physiology.

[38]  R. Khalil,et al.  Protein kinase C isoforms as specific targets for modulation of vascular smooth muscle function in hypertension. , 2005, Biochemical pharmacology.

[39]  W. Seeger,et al.  Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.

[40]  S. Archer,et al.  Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. , 2005, The Journal of clinical investigation.

[41]  S. Oparil,et al.  Endothelin-A Receptor Blockade Prevents and Partially Reverses Neonatal Hypoxic Pulmonary Vascular Remodeling , 2005, Pediatric Research.

[42]  J. Dyck,et al.  Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell Apoptosis , 2004, Circulation research.

[43]  K. Morris,et al.  Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[44]  A. Stopeck,et al.  Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. , 2004, Leukemia research.

[45]  H. Coleman,et al.  Prostacyclin and endothelium-dependent hyperpolarization. , 2004, Pharmacological research.

[46]  R. Marthan,et al.  Role of α-Adrenergic Receptors in the Effect of the β-Adrenergic Receptor Ligands, CGP 12177, Bupranolol, and SR 59230A, on the Contraction of Rat Intrapulmonary Artery , 2004, Journal of Pharmacology and Experimental Therapeutics.

[47]  R. Budhiraja,et al.  Endothelial Dysfunction in Pulmonary Hypertension , 2004, Circulation.

[48]  R. Marthan,et al.  Role of alpha-adrenergic receptors in the effect of the beta-adrenergic receptor ligands, CGP 12177, bupranolol, and SR 59230A, on the contraction of rat intrapulmonary artery. , 2004, The Journal of pharmacology and experimental therapeutics.

[49]  Larry W. Moreland,et al.  Nuclear factor of activated T-cells , 2004 .

[50]  W. Seeger,et al.  Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. , 2004, American journal of respiratory and critical care medicine.

[51]  R. Khalil,et al.  Ca2+ antagonist-insensitive coronary smooth muscle contraction involves activation of ϵ-protein kinase C-dependent pathway , 2003 .

[52]  T. Phang,et al.  Hypoxia induces different genes in the lungs of rats compared with mice. , 2003, Physiological genomics.

[53]  R. Khalil,et al.  Ca2+ antagonist-insensitive coronary smooth muscle contraction involves activation of epsilon-protein kinase C-dependent pathway. , 2003, American journal of physiology. Cell physiology.

[54]  M. Yanagisawa,et al.  Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[55]  J. Dyck,et al.  Dichloroacetate, a Metabolic Modulator, Prevents and Reverses Chronic Hypoxic Pulmonary Hypertension in Rats: Role of Increased Expression and Activity of Voltage-Gated Potassium Channels , 2002, Circulation.

[56]  S. Narumiya,et al.  Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. , 2001, American journal of respiratory and critical care medicine.

[57]  P. Hirth,et al.  Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[58]  R. Nagai,et al.  Vascular smooth muscle cell phenotypes in primary pulmonary hypertension. , 2001, The European respiratory journal.

[59]  T. Jeffery,et al.  Comparison of pulmonary vascular function and structure in early and established hypoxic pulmonary hypertension in rats. , 2001, Canadian journal of physiology and pharmacology.

[60]  J. Granger,et al.  [Ca(2+)](i) signaling in renal arterial smooth muscle cells of pregnant rat is enhanced during inhibition of NOS. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[61]  L. Shimoda,et al.  L-type Ca(2+) channels, resting [Ca(2+)](i), and ET-1-induced responses in chronically hypoxic pulmonary myocytes. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[62]  R. Khalil,et al.  Gender-specific reduction in contractility and [Ca(2+)](i) in vascular smooth muscle cells of female rat. , 2000, American journal of physiology. Cell physiology.

[63]  L. Shimoda,et al.  Altered pulmonary vasoreactivity in the chronically hypoxic lung. , 2000, Physiological research.

[64]  J. Granger,et al.  Decreased endothelium-dependent vascular relaxation during reduction of uterine perfusion pressure in pregnant rat. , 2000, Hypertension.

[65]  D. Beasley,et al.  Hypoxia stimulates proliferation and interleukin-1alpha production in human vascular smooth muscle cells. , 1999, The American journal of physiology.

[66]  H. Itoh,et al.  Effects of the endothelin ET(A) receptor antagonist, TA-0201, on pulmonary arteries isolated from hypoxic rats. , 1999, European journal of pharmacology.

[67]  N. Voelkel,et al.  Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. , 1999, The Journal of clinical investigation.

[68]  R. Busse,et al.  Nitric oxide, nitric oxide synthase, and hypertensive vascular disease , 1999, Current hypertension reports.

[69]  C. Hsieh,et al.  Prevention of Hypoxia-Induced Pulmonary Hypertension by Enhancement of Endogenous Heme Oxygenase-1 in the Rat. • 238 , 1997, Pediatric Research.

[70]  R. McIntyre,et al.  Mechanistic imbalance of pulmonary vasomotor control in progressive lung injury. , 1996, Surgery.

[71]  P. Braquet,et al.  Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. , 1991, The Journal of clinical investigation.

[72]  T. Lincoln,et al.  cGMP-dependent protein kinase mediates the reduction of Ca2+ by cAMP in vascular smooth muscle cells. , 1990, The American journal of physiology.

[73]  B. Groves,et al.  Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. , 1989, Circulation.

[74]  M. Gillespie,et al.  Vascular hyperresponsiveness in perfused lungs from monocrotaline-treated rats. , 1986, The American journal of physiology.